113 Results

People

  1. Dang
    Dang
  2. Baselga
    Baselga
  3. Hudis
    Hudis
  4. Modi
    Modi
  5. Chandarlapaty
    Chandarlapaty
  6. Morrow
    Morrow
  7. Norton
    Norton
  8. Patil
    Patil
  9. Barrio
    Barrio
  10. Fornier
    Fornier

Groups

  1. Department of Medicine (76)
  2. Solid Tumor Oncology Division (72)
  3. Breast Medicine Service (46)
  4. Survivorship Research (43)
  5. GSK Faculty (18)
  6. Population Sciences Research Program (18)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (16)
  8. Epidemiology and Biostatistics (16)
  9. Division of Subspecialty Medicine (14)
  10. Department of Pathology and Laboratory Medicine (12)
  1. "pertuzumab"
Formats
  1. Journal Article (91)
  2. Review (17)
  3. Editorial (4)
  4. Guidelines (1)
Groups
  1. Department of Medicine (76)
  2. Solid Tumor Oncology Division (72)
  3. Breast Medicine Service (46)
  4. Survivorship Research (43)
  5. GSK Faculty (18)
  6. Population Sciences Research Program (18)

More Groups

People
  1. Chau Dang (18)
  2. Jose Baselga (17)
  3. Clifford Hudis (14)
  4. Shanu Modi (12)
  5. Monica Morrow (8)
  6. Sarat Chandarlapaty (8)

More People

Years
  1. 2025 (4)
  2. 2024 (19)
  3. 2023 (9)
  4. 2022 (8)
  5. 2021 (8)
  6. 2020 (3)

More Years

Publications
  1. Breast Cancer Research and Treatment (11)
  2. Journal of Clinical Oncology (10)
  3. Annals of Oncology (9)
  4. The Oncologist (6)
  5. Cancer Discovery (4)
  6. New England Journal of Medicine (4)

More Publications

Publishers
  1. Elsevier Inc. (19)
  2. Springer (18)
  3. Oxford University Press (15)
  4. American Society of Clinical Oncology (11)
  5. American Association for Cancer Research (6)
  6. Elsevier Science, Inc. (5)

More Publishers

Results (113)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The influence of glycans-specific bioconjugation on the FcγRI binding and in vivo performance of (89)Zr-DFO-pertuzumab
    Journal Article

    Vivier, D.; Fung, K.; Rodriguez, C.; Adumeau, P.; Ulaner, G. A.; Lewis, J. S.; Sharma, S. K.; Zeglis, B. M.
    Theranostics (2020)

    Fulltext@MSK | Save
  • Excellent locoregional control in inflammatory breast cancer with a personalized radiation therapy approach
    Journal Article

    Stecklein, S. R.; Rosso, K. J.; Nuanjing, J.; Tadros, A. B.; Weiss, A.; DeSnyder, S. M.; Kuerer, H. M.; Teshome, M.; Buchholz, T. A.; Stauder, M. C.; more...
    Practical Radiation Oncology (2019)

    Fulltext@MSK | Save
  • Temporal modulation of HER2 membrane availability increases pertuzumab uptake and pretargeted molecular imaging of gastric tumors
    Journal Article

    Pereira, P. M. R.; Mandleywala, K.; Ragupathi, A.; Carter, L. M.; Goos, J. A. C. M.; Janjigian, Y. Y.; Lewis, J. S.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow-up
    Journal Article

    Wang, R.; Smyth, L. M.; Iyengar, N.; Chandarlapaty, S.; Modi, S.; Jochelson, M.; Patil, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: The SAFE-HEaRt study
    Journal Article

    Lynce, F.; Barac, A.; Geng, X.; Dang, C.; Yu, A. F.; Smith, K. L.; Gallagher, C.; Pohlmann, P. R.; Nunes, R.; Herbolsheimer, P.; more...
    Breast Cancer Research and Treatment (2019)

    Fulltext@MSK | Save
  • Precision oncology giveth and precision oncology taketh away
    Editorial

    Saltz, L. B.
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review
    Review

    Singh, R. R.; Goldberg, J.; Varghese, A. M.; Yu, K. H.; Park, W.; O'Reilly, E. M.
    Cancer Treatment Reviews (2019)

    Fulltext@MSK | Save
  • Neoadjuvant pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER-2/neu-positive breast cancer: A retrospective, single institution experience
    Journal Article

    Murthy, R. K.; Raghavendra, A. S.; Hess, K. R.; Fujii, T.; Lim, B.; Barcenas, C. H.; Zhang, H.; Chavez-Mac-Gregor, M.; Mittendorf, E. A.; Litton, J. K.; more...
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save
  • Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): A phase II, open-label, multicenter, multinational cardiac safety study
    Journal Article

    Swain, S. M.; Ewer, M. S.; Viale, G.; Delaloge, S.; Ferrero, J. M.; Verrill, M.; Colomer, R.; Vieira, C.; Werner, T. L.; Douthwaite, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • 4th Symposium on Primary Breast Cancer in Older Women. Theme: Putting personalized care into practice (Held: 3 March 2017)
    Journal Article

    Cheung, K. L.; Morgan, D.; Brain, E.; Poortmans, P.; Parks, R.; Korc-Grodzicki, B.; Ugolini, F.; Shakir, T.; Tsang, J.; Stone, H.; more...
    Breast Cancer Management (2017)

    Fulltext@MSK | Save